OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

39 - 2002, what about 135 - 2000? Have been a long term holder since 98, and just know these will make me seriously rich

UP 9.23% so far today.

OXFORD BIOMEDICA ANNOUNCES POSITIVE INTERIM PHASE II RESULTS WITH TROVAX IN COLORECTAL CANCER

Oxford, UK - 1 September 2004: Oxford BioMedica (LSE: OXB) announced today that the primary endpoints have been achieved at the interim stage of two Phase II trials in patients with Stage IV colorectal cancer receiving TroVax alongside chemotherapy. TroVax is the Company's novel cancer immunotherapy product against the tumour associated antigen 5T4. The primary endpoints are safety and demonstrable anti-tumour immune responses against the 5T4 tumour antigen.

The results from an interim analysis of both trials, initiated in 2003, showed that the combination of TroVax and standard of care chemotherapy is safe and that patients mount specific immune responses to the 5T4 antigen. Full recruitment is imminent across both trials with 36 of 37 projected patients
enrolled. The objective is to have ten evaluable patients in each setting. The interim results are based on 13 patients in total, who have reached an interim analysis point defined as four TroVax immunisations and more than eight cycles
of chemotherapy. There have been no serious adverse events associated with TroVax treatment and the product was well tolerated. 11 of the 13 patients (85%) mounted antibody and/or cellular immune responses to the 5T4 tumour antigen
following four immunisations with TroVax.

The Company expects to report full safety and immunological data in mid-2005 when all patients will have received 12 cycles of chemotherapy and 6 doses of TroVax. At this time, tumour response rates will also be determined.

TroVax plus IFL chemotherapy

The protocol of the first Phase II trial is six immunisations of TroVax alongside chemotherapy cycles of irinotecan, 5-fluorouracil (5FU) and leucovorin (a combination referred to as IFL). A total of 19 patients have been enrolled.
Ten patients have reached the interim analysis point. Nine out of ten patients (or 90%) have mounted specific anti-tumour immunological responses to the 5T4 antigen.

TroVax plus FOLFOX chemotherapy

The second Phase II trial protocol is similarly six immunisations of TroVax alongside cycles of oxaliplatin, 5FU and leucovorin (referred to as FOLFOX). The trial is fully recruited at 17 patients. Three patients have reached the interim
analysis point and two of these (or 67%) have shown anti-5T4 immune responses to date.

Commenting on the Phase II results, Prof. Alan Kingsman, Chief Executive of Oxford BioMedica, said, 'We are very pleased with the progress of our first Phase II trials with TroVax. The high number of anti-5T4 responses at this interim stage suggests that patients are able to mount an anti-tumour immune
response even in the context of chemotherapy treatment. In our earlier Phase I/ II trials, it was clear that anti-5T4 immune responses correlated with improved patient survival. We now feel confident that TroVax has a role to play in the
treatment of colorectal cancer.'


-Ends-

Started with a nice rise, pity it didn't hold on to it.

OXB see value generation this year!

May yet finish up on the day I suppose.

Well suckered in again and MMs that bit richer!!

Sold most of mine & left my profit in, I'll buy more again if it goes lower.

too early to sell

one i am intrested in buying in to,but need to no more about.seen an article on this company ,seems its all in the future 12/24 months ahead,could be a bright future.there 2 presant drugs on trial there in there 2nd stage of development , is that right , dd.

daves dazzlers

More than 2, read this thread, read the RNS & AFX releases & you will see.

cheers apple will do.

Today's FT comments on the OXB results

FT Comment

* Biotechnology is anewsflow-driven sector and Oxford Biomedica has had little to say this year. But there is plenty of newsflow in the pipeline. First, there is a licensing deal for TroVax, the treatment that accounts for about 90 per cent of the company's valuation. Then there is key clinical data on whether TroVax actually improves survival rates in chemotherapy patients, as well as clinical data on MetXia, a more risky gene therapy treatment for cancer. Finally, there are two new products going into clinical trials next year and three more to follow. Analysts attribute no value to pre-clinical products, so each new trial could add value. Whether they do so is another matter. Investors, not analysts, set the price; and, in the current risk-averse environment, they are only interested in treatments that are in the final stages of development. In that case, restoring Oxford Biomedica's dwindling share price rests on Mr Woolf's ability to strike a lucrative TroVax deal.

Well don't know about OXB pulling it off with battle against cancer way sp is heading they'd be better off doing something about depression!!
Well will see how much small share holders get screwed for next week. But never know AK and gang might actually deliver something. Well can but dream.

From the Daily Mail Broker Buys. Code Securities says BUY at 18p "possible news on gene therapy, and licensing deals".

Thanks Janus

"possible news on gene therapy, and licensing deals"
Same all same!!

Nice volumes today, hope it can maintain momentum.
Lets see what Tues brings!!

Looking good, glad I left my profit in.

Well they aint falling over themselves too trade OXB this morning, can take it yesterday was a momentary halt in slide. Predict another neg day, hope I'm wrong.

By time good news comes we can look forward to 100% increase in sp, from say 1p to 2p!!
Come AK gives something positive to go on.

cheers for all the info on this,,,,,but it takes some reading for one that ,,,,,,does`nt no to much about this sector.